[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].

Pabinger I, Gastl G, Steurer M, Sormann S, Fillitz M, Friedl J, Geissler D, Geissler K, Greil R, Knöbl P, Kozek-Langenecker S, Krippl P, Kyrle P, Lang A, Linkesch W, Ludwig H, Müller M, Panzer S, Pittermann E, Thaler J, Weltermann A. Wien Klin Wochenschr. 2012 Feb,124(3-4):111-23. doi: 10.1007/s00508-012-0123-3. Epub 2012 Mar 3.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

Aapro M, Molassiotis A, Dicato M, PelГЎez I, RodrГ­guez-Lescure ГЃ, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F Ann Oncol. 2012 Aug,23(8):1986-92. Epub 2012 Mar 6.

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label phase 3 non-inferiority trial.

Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, et al. Lancet. 2012 May 12,379(9828):1791-9. doi: 10.1016/S0140-6736(11)61940-5. Epub 2012 Apr 4.

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled multicenter multinational double-blinded phase II trial.

Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, et al. BMC Cancer. 2012 Apr 11,12:144. doi: 10.1186/1471-2407-12-144.

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R Haematologica. 2012 Sep,97(9):1431-8. Epub 2012 Apr 17.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-J?drzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, BladГ© J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, et al. N Engl J Med. 2012 May 10,366(19):1759-69. doi: 10.1056/NEJMoa1112704.

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

Lang I, Inbar MJ, KahГЎn Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C. Eur J Cancer. 2012 Nov,48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26.

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R. Oncologist. 2012,17(7):e13-7. doi: 10.1634/theoncologist.2012-0115. Epub 2012 Jun 27.

[Safety of immunosuppressants].

Psenak O, Studnicka-Benke A, Greil R. Z Rheumatol. 2012 Jul,71(5):420-9. doi: 10.1007/s00393-012-0990-z.

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.

Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A. BMC Cancer. 2012 Aug 9,12:349. doi: 10.1186/1471-2407-12-349.